Haleon plc (NYSE:HLN) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lowered its position in Haleon plc (NYSE:HLN) by 8.5% in the third quarter, Holdings Channel.com reports. The institutional investor owned 1,788,741 shares of the company’s stock after selling 165,563 shares during the period. The Manufacturers Life Insurance Company’s holdings in Haleon were worth $18,925,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of HLN. Fortitude Family Office LLC acquired a new stake in Haleon during the 3rd quarter worth $28,000. Cultivar Capital Inc. purchased a new position in shares of Haleon during the second quarter worth about $40,000. Hexagon Capital Partners LLC increased its position in Haleon by 66.6% in the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after acquiring an additional 2,677 shares during the period. Prospera Private Wealth LLC purchased a new stake in Haleon during the 3rd quarter valued at approximately $57,000. Finally, BOKF NA lifted its position in Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after acquiring an additional 2,842 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Price Performance

Shares of NYSE HLN opened at $9.66 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The firm has a market capitalization of $43.73 billion, a P/E ratio of 28.40, a PEG ratio of 2.94 and a beta of 0.30. The company’s fifty day moving average is $9.92 and its two-hundred day moving average is $9.42.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on HLN shares. UBS Group raised Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Morgan Stanley upped their price objective on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Finally, Berenberg Bank started coverage on shares of Haleon in a report on Tuesday, August 6th. They set a “buy” rating for the company. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Haleon has a consensus rating of “Buy” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.